Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Malignant Melanoma

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 33 articles:
HTML format
Text format



Single Articles


    August 2018
  1. TURAJLIC S, Larkin J
    Immunotherapy for Melanoma Metastatic to the Brain.
    N Engl J Med. 2018;379:789-790.
    PubMed     Text format    


  2. TAWBI HA, Forsyth PA, Algazi A, Hamid O, et al
    Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain.
    N Engl J Med. 2018;379:722-730.
    PubMed     Text format     Abstract available


  3. BARKER CA
    Adjuvant Pembrolizumab in Resected Stage III Melanoma.
    N Engl J Med. 2018;379:593.
    PubMed     Text format    



  4. Adjuvant Pembrolizumab in Resected Stage III Melanoma.
    N Engl J Med. 2018;379:593-595.
    PubMed     Text format    


    April 2018

  5. More on Adjuvant Therapy in Resected Melanoma.
    N Engl J Med. 2018;378:1656-1657.
    PubMed     Text format    


  6. EGGERMONT AMM, Blank CU, Mandala M, Long GV, et al
    Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma.
    N Engl J Med. 2018 Apr 15. doi: 10.1056/NEJMoa1802357.
    PubMed     Text format     Abstract available


    February 2018
  7. WEBER J, Qureshi A, Ascierto PA
    Adjuvant Therapy in Resected Melanoma.
    N Engl J Med. 2018;378:680.
    PubMed     Text format    


  8. MARIA ARJ, Viegas Dias C, Heleno B
    Adjuvant Therapy in Resected Melanoma.
    N Engl J Med. 2018;378:679.
    PubMed     Text format    


  9. THOMSON N, Doerr R, Martin MG
    Adjuvant Therapy in Resected Melanoma.
    N Engl J Med. 2018;378:678-9.
    PubMed     Text format    


  10. SLADDEN M, Zagarella S, Bigby M
    Adjuvant Therapy in Resected Melanoma.
    N Engl J Med. 2018;378:678.
    PubMed     Text format    



  11. Adjuvant Therapy in Resected Melanoma.
    N Engl J Med. 2018;378:678-680.
    PubMed     Text format    


    January 2018
  12. CAULLEY L, Balch CM, Ross MI, Robert C, et al
    Management of Sentinel-Node Metastasis in Melanoma.
    N Engl J Med. 2018;378:85-88.
    PubMed     Text format    


    December 2017
  13. ALEGRE-DEL-REY EJ, de la Nogal Fernandez B, Briceno-Casado P
    Nivolumab and Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2017;377:2503.
    PubMed     Text format    


  14. RYU H, Lee HJ
    Nivolumab and Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2017;377:2503.
    PubMed     Text format    


  15. KOURKOUMPETIS T, Jarbrink-Sehgal ME
    Melanoma Metastatic to the Duodenum.
    N Engl J Med. 2017;377:e34.
    PubMed     Text format    


  16. WOLCHOK JD, Rollin L, Larkin J
    Nivolumab and Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2017;377:2503-2504.
    PubMed     Text format    


    November 2017
  17. SCHUCHTER LM
    Adjuvant Melanoma Therapy - Head-Spinning Progress.
    N Engl J Med. 2017;377:1888-1890.
    PubMed     Text format    


    September 2017
  18. WOLCHOK JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, et al
    Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.
    N Engl J Med. 2017 Sep 11. doi: 10.1056/NEJMoa1709684.
    PubMed     Text format     Abstract available


  19. WEBER J, Mandala M, Del Vecchio M, Gogas HJ, et al
    Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
    N Engl J Med. 2017 Sep 10. doi: 10.1056/NEJMoa1709030.
    PubMed     Text format     Abstract available


  20. LONG GV, Hauschild A, Santinami M, Atkinson V, et al
    Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
    N Engl J Med. 2017 Sep 10. doi: 10.1056/NEJMoa1708539.
    PubMed     Text format     Abstract available


    August 2017
  21. BILIMORIA KY, Russell MC, Hyngstrom J
    Melanoma Sentinel-Node Metastasis.
    N Engl J Med. 2017;377:891.
    PubMed     Text format    


  22. FARIES MB, Cochran AJ, Thompson JF
    Melanoma Sentinel-Node Metastasis.
    N Engl J Med. 2017;377:892.
    PubMed     Text format    



  23. Melanoma Sentinel-Node Metastasis.
    N Engl J Med. 2017;377:891-2.
    PubMed     Text format    


    July 2017
  24. COSTELLO CM, Pittelkow MR, Mangold AR
    Acral Melanoma and Mechanical Stress on the Plantar Surface of the Foot.
    N Engl J Med. 2017;377:395-396.
    PubMed     Text format    


    June 2017
  25. COIT D
    The Enigma of Regional Lymph Nodes in Melanoma.
    N Engl J Med. 2017;376:2280-2281.
    PubMed     Text format    


  26. FARIES MB, Thompson JF, Cochran AJ, Andtbacka RH, et al
    Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma.
    N Engl J Med. 2017;376:2211-2222.
    PubMed     Text format     Abstract available


    May 2017
  27. GONG HZ, Li J
    Melanoma of the Foot.
    N Engl J Med. 2017;376:1867.
    PubMed     Text format    


    February 2017
  28. KRISTENSEN VN
    The Antigenicity of the Tumor Cell - Context Matters.
    N Engl J Med. 2017;376:491-493.
    PubMed     Text format    


    January 2017
  29. COPUR MS, Ramaekers R, Crockett D
    Ipilimumab Adjuvant Therapy in Melanoma.
    N Engl J Med. 2017;376:398-9.
    PubMed     Text format    


  30. IANIRO G, Gasbarrini A, Cammarota G
    Ipilimumab Adjuvant Therapy in Melanoma.
    N Engl J Med. 2017;376:398.
    PubMed     Text format    


  31. EGGERMONT AMM, Suciu S, Testori A, et al., et al
    Ipilimumab Adjuvant Therapy in Melanoma.
    N Engl J Med. 2017;376:399.
    PubMed     Text format    


    November 2016
  32. JOHNSON DB, Balko JM, Compton ML, Chalkias S, et al
    Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
    N Engl J Med. 2016;375:1749-1755.
    PubMed     Text format     Abstract available


    October 2016
  33. EGGERMONT AM, Chiarion-Sileni V, Grob JJ, Dummer R, et al
    Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy.
    N Engl J Med. 2016.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: